Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study

References

• Holmes CB, Losina E, Walensky RP, et al. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003;36:652–662. doi:10.1086/367655.
   PubMed Web of Science ®Google Scholar
• Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J. 2004;170:229–238.
   PubMed Web of Science ®Google Scholar
• When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–1363. doi:10.1016/S0140-6736(09)60612-7.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Fact sheet – latest statistics on the status of the AIDS epidemic; 2017. Available from: http://www.unaids.org/.
   Google Scholar
• NCAIDS, NCSTD, China CDC. Update on the AIDS/STD epidemic in China in July, 2017. Chin J AIDS STD. 2017;775. doi:10.13419/j.cnki.aids.2017.09.01.
   Google Scholar
• Luo B, Sun J, Cai R, et al. Spectrum of opportunistic infections and risk factors for in-hospital mortality of admitted AIDS patients in Shanghai. Medicine. 2016;95:e3802. doi:10.1097/MD.0000000000003802.
   PubMed Web of Science ®Google Scholar
• Vanittanakom N, Cooper Jr CR, Fisher MC, et al. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19:95–110. doi:10.1128/CMR.19.1.95-110.2006.
   PubMed Web of Science ®Google Scholar
• Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013;13:464. doi:10.1186/1471-2334-13-464.
   PubMed Web of Science ®Google Scholar
• Wong KH, Lee SS. Comparing the first and second hundred AIDS cases in Hong Kong. Singap Med J. 1998;39:236–240.
   PubMedGoogle Scholar
• Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013;175:57–67. doi:10.1007/s11046-012-9577-0.
   PubMed Web of Science ®Google Scholar
• Cooper CR, Vanittanakom N. Insights into the pathogenicity of Penicillium marneffei. Future Microbiol. 2008;3:43–55. doi:10.2217/17460913.3.1.43.
   PubMed Web of Science ®Google Scholar
• Cuong do D, Thorson A, Sönnerborg A, et al. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. Scand J Infect Dis. 2012;44:201–208. doi:10.3109/00365548.2011.631937.
   PubMedGoogle Scholar
• Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011;52:945–952. doi:10.1093/cid/cir028.
   PubMed Web of Science ®Google Scholar
• Hanf M, Adenis A, Couppie P, et al. HIV-associated histoplasmosis in French Guiana: recent infection or reactivation? Aids. 2010;24:1777–1778. doi:10.1097/QAD.0b013e32833999c9.
   PubMed Web of Science ®Google Scholar
• Zheng J, Gui X, Cao Q, et al. A clinical study of acquired immunodeficiency syndrome associated penicillium marneffei infection from a non-endemic area in China. PloS one. 2015;10:e0130376. doi:10.1371/journal.pone.0130376.
   PubMed Web of Science ®Google Scholar
• Wang YF, Xu H-F, Han Z-G, et al. Serological surveillance for Penicillium marneffei infection in HIV-infected patients during 2004–2011 in Guangzhou, China. Clin Microbiol Infec. 2015;21:484–489. doi:10.1016/j.cmi.2014.12.014.
   PubMed Web of Science ®Google Scholar
• Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet. 2006;367:1256–1261. doi:10.1016/S0140-6736(06)68541-3.
   PubMed Web of Science ®Google Scholar
• Beraud G, Smadja D, Abel S, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994–2006. Am J Trop Med Hyg. 2009;80:583–587. doi: 10.4269/ajtmh.2009.80.583
   PubMed Web of Science ®Google Scholar
• Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428–1434. doi:10.1016/S0140-6736(04)17225-5.
   PubMed Web of Science ®Google Scholar
• Crook AM, Turkova A, Musiime V, et al. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med. 2016;14:50. doi:10.1186/s12916-016-0593-7.
   PubMed Web of Science ®Google Scholar
• Hasse B, Walker AS, Fehr J, et al. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Ch. 2014;58:2363–2368. doi:10.1128/AAC.01868-13.
   PubMed Web of Science ®Google Scholar
• Cheng W, Wu Y, Wen Y, et al. Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. B World Health Organ. 2015;93:152–160. doi:10.2471/BLT.14.142745.
   PubMed Web of Science ®Google Scholar
• Li K, Li T, Yang S-S, et al. Deletion of nudB causes increased susceptibility to antifolates in escherichia coli and salmonella enterica. Antimicrob Agents Ch. 2017;61:e02378–16. doi:10.1128/AAC.02378-16.
   PubMed Web of Science ®Google Scholar
• Zang X, Tang H, Min JE, et al. Cost-Effectiveness of the ‘One4All’ HIV linkage intervention in Guangxi Zhuang autonomous region, China. PloS one. 2016;11:e0167308. doi:10.1371/journal.pone.0167308.
   PubMed Web of Science ®Google Scholar
• Jiang J, Meng S, Huang S, et al. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin Microbiol Infec. 2019;25:233–241. doi:10.1016/j.cmi.2018.04.018.
   PubMed Web of Science ®Google Scholar
• Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. Aids. 2015;29:1391–1399. doi:10.1097/QAD.0000000000000705.
   PubMed Web of Science ®Google Scholar
• Jamaiah I, Rohela M, Tok EL, et al. Pneumocystis carinii (jirovecii) pneumonia (PCP): the most common opportunistic infection observed in HIV/AIDS cases at the University Malaya Medical Centre, Kuala Lumpur, Malaysia. SE Asian J Trop Med. 2012;43:825–831.
   PubMed Web of Science ®Google Scholar
• Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis. 2011;11:516–524. doi:10.1016/S1473-3099(11)70097-4.
   PubMed Web of Science ®Google Scholar
• Zhou F, Bi X, Zou X, et al. Retrospective analysis of 15 cases of Penicilliosis marneffei in a southern China hospital. Mycopathologia. 2014;177:271–279. doi:10.1007/s11046-014-9737-5.
   PubMed Web of Science ®Google Scholar
• Chariyalertsak S, Sirisanthana T, Supparatpinyo K, et al. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis. 1997;24:1080–1086. doi: 10.1086/513649
   PubMed Web of Science ®Google Scholar
• Bulterys PL, Le T, Quang VM, et al. Environmental predictors and incubation period of AIDS-associated penicillium marneffei infection in Ho Chi Minh city, Vietnam. Clin Infect Dis. 2013;56:1273–1279. doi:10.1093/cid/cit058.
   PubMed Web of Science ®Google Scholar
• Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74:730–734. doi:10.4065/74.7.730.
   PubMed Web of Science ®Google Scholar
• Meir Z, Osherov N. Vitamin biosynthesis as an antifungal target. J Fungi. 2018;4: 72. doi:10.3390/jof4020072.
   Web of Science ®Google Scholar
• Creemers-Schild D, Kroon FP, Kuijper EJ, et al. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. Infection. 2016;44:291–299. doi:10.1007/s15010-015-0851-1.
   PubMed Web of Science ®Google Scholar